From Name:
From Email:
To Name:
To Email:

Optional Message:


Maintenance pazopanib in ovarian cancer: No survival benefit

from Cancer Network (Free login required)

Maintenance therapy with the oral agent pazopanib improved progression free survival by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical Oncology. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063